Amicus Therapeutics (FOLD) shares are soaring 5.53% in pre-market trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The biotechnology company, focused on developing treatments for rare diseases, reported better-than-expected earnings and revenue, demonstrating strong commercial execution and financial performance.
For the third quarter ended September 30, 2025, Amicus reported total revenue of $169.1 million, representing a 17% increase at constant exchange rates compared to the same period last year. This figure surpassed the analysts' consensus estimate of $165.7 million. The company achieved a positive GAAP net income of $17 million, or $0.06 per share, a significant improvement from a loss in the previous year. On an adjusted basis, earnings per share came in at $0.17, substantially beating the expected $0.04 per share.
The strong performance was driven by robust sales of the company's key products. Galafold sales increased 15% year-over-year to $138.3 million, while Pombiliti + Opfolda sales rose 45% to $30.7 million. Amicus also reported a healthy cash position of $264 million, an increase of $33 million from the previous quarter. Looking ahead, the company reaffirmed its full-year 2025 guidance, projecting total revenue growth of 15% to 22% and anticipating positive GAAP net income in the second half of 2025. These results and outlook underscore Amicus Therapeutics' solid market position and growth potential in the rare disease treatment sector, likely contributing to investor optimism and the stock's pre-market surge.
Comments